GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agios Pharmaceuticals Inc (NAS:AGIO) » Definitions » E10

Agios Pharmaceuticals (Agios Pharmaceuticals) E10 : $-2.84 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Agios Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was $-1.450. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.84 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-05-26), Agios Pharmaceuticals's current stock price is $31.50. Agios Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was $-2.84. Agios Pharmaceuticals's Shiller PE Ratio of today is .


Agios Pharmaceuticals E10 Historical Data

The historical data trend for Agios Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agios Pharmaceuticals E10 Chart

Agios Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -1.85 -2.21 -2.70

Agios Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -2.47 -2.59 -2.70 -2.84

Competitive Comparison of Agios Pharmaceuticals's E10

For the Biotechnology subindustry, Agios Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agios Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agios Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agios Pharmaceuticals's Shiller PE Ratio falls into.



Agios Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Agios Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-1.45/131.7762*131.7762
=-1.450

Current CPI (Mar. 2024) = 131.7762.

Agios Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.540 100.560 -0.708
201409 0.100 100.428 0.131
201412 -0.760 99.070 -1.011
201503 -0.130 99.621 -0.172
201506 -0.850 100.684 -1.112
201509 -1.070 100.392 -1.405
201512 -1.080 99.792 -1.426
201603 -0.610 100.470 -0.800
201606 -1.470 101.688 -1.905
201609 -1.630 101.861 -2.109
201612 -1.340 101.863 -1.734
201703 -1.560 102.862 -1.999
201706 -1.780 103.349 -2.270
201709 -1.590 104.136 -2.012
201712 -1.810 104.011 -2.293
201803 -1.630 105.290 -2.040
201806 -1.190 106.317 -1.475
201809 -1.630 106.507 -2.017
201812 -1.580 105.998 -1.964
201903 -1.590 107.251 -1.954
201906 -1.870 108.070 -2.280
201909 -1.810 108.329 -2.202
201912 -1.600 108.420 -1.945
202003 -0.590 108.902 -0.714
202006 -1.310 108.767 -1.587
202009 -1.430 109.815 -1.716
202012 -1.410 109.897 -1.691
202103 26.950 111.754 31.778
202106 -1.410 114.631 -1.621
202109 -1.560 115.734 -1.776
202112 -1.740 117.630 -1.949
202203 -1.740 121.301 -1.890
202206 -1.680 125.017 -1.771
202209 -1.490 125.227 -1.568
202212 0.670 125.222 0.705
202303 -1.470 127.348 -1.521
202306 -1.510 128.729 -1.546
202309 -1.640 129.860 -1.664
202312 -1.720 129.419 -1.751
202403 -1.450 131.776 -1.450

Add all the adjusted EPS together and divide 10 will get our e10.


Agios Pharmaceuticals  (NAS:AGIO) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Agios Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of Agios Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Agios Pharmaceuticals (Agios Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
88 Sidney Street, Cambridge, MA, USA, 02139
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Executives
Brian Goff director, officer: Chief Executive Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
Sarah Gheuens officer: Chief Medical Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James William Burns officer: Chief Legal Officer C/O AGIOS PHARMACEUTICALS, 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jacqualyn A Fouse director C/O DICK'S SPORTING GOODS, 345 COURT STREET, CORAOPOLIS PA 15108
Tsveta Milanova officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY SREET, CAMBRIDGE MA 02139
Cecilia Jones officer: Chief Financial Officer C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Kaye I Foster-cheek director JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Washburn Theodore James Jr. officer: Principal Accounting Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey D Capello director C/O NEOGEN CORP., 620 LESHER PLACE, LANSING MI 48912
Catherine E. Owen director 1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
David P Schenkein director, 10 percent owner, officer: Chief Executive Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Rahul D. Ballal director 116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Richa Poddar officer: Chief Commercial Officer C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
Carman Alenson officer: Principal Accounting Officer 88 SIDNEY STREET, CAMBRIDGE MA 02139

Agios Pharmaceuticals (Agios Pharmaceuticals) Headlines

From GuruFocus